Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice

Danica Michalickova,Pavel Jansa,Miroslava Bursová,Tomas Hlozek,Radomír Čabala,Jan Hartinger,David Ambrož,Aschermann M,Jaroslav Lindner,Aleš Linhart,Ondrej Slanar,Elke H. J. Krekels

Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice

2020

Danica Michalickova
Pavel Jansa
Miroslava Bursová
Tomas Hlozek
Radomír Čabala
Jan Hartinger
David Ambrož
Aschermann M
Jaroslav Lindner
Aleš Linhart
Ondrej Slanar
Elke H. J. Krekels

Pharmacokinetic data for riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) have previously been reported from randomized clinical trials, which may not fully reflect ...

Keywords:

Medicine
Chronic thromboembolic pulmonary hypertension
NONMEM
Population
Metabolite
Pharmacokinetics
Riociguat
Randomized controlled trial
Internal medicine
Renal function
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations